Shareholders' Equity (Tables)

12 Months Ended

Dec. 31, 2023

Shareholders' Equity [Abstract]

Schedule of Issued and Outstanding

The following table presents the number of authorized and issued and outstanding shares as of each reporting date for each class of shares:

	December 31, 2023				December 31, 2022
	Authorized		Issued and Outstanding		Authorized		Issued and Outstanding
Ordinary shares		100,000,000		57,778,628		100,000,000		55,094,237
Total		100,000,000		57,778,628		100,000,000		55,094,237

Schedule of Shared - Based Payments to Employees

The Company recorded an expense of $642 attributable to RSUs awards during the reporting period, which was included in Research and development expenses, net.

	Year ended December 31, 2023
				Weighted
	Number of			average
	share-based			exercise
		payment			Price (in
		awards			U.S. Dollar)
Outstanding at beginning of year		5,115,910		$	15.19
Changes during the year:
Granted		545,105			11.22
Exercised		(286,141	)		3.02
Forfeited		(153,480	)		19.36
Outstanding at end of year		5,221,394			13.34
Aggregate intrinsic value	$	5,112			-
Exercisable at end of year		3,621,783			10.43
Aggregate intrinsic value	$	5,110			-

Schedule of Black-Scholes Option-Pricing Model

he assumptions used for the year ended December 31, 2023 and year ended at December 31, 2022 are as follows:

	Year ended December 31, 2023		Year ended December 31, 2022
Dividend yield		0		0
Expected volatility		74.26% - 81.80%		50.75% - 52.75%
Risk-free interest rate		3.45% - 4.28%		1.52% - 4.34%
Expected term (years)		6.25 - 10		5.52–10

Schedule of Information Concerning Outstanding and Exercisable Awards

The following table summarizes information concerning outstanding and exercisable awards as of December 31, 2023:

December 31, 2023
Awards outstanding							Awards exercisable
		Number of			Weighted		Number of		Weighted
		awards			average		awards		average
		outstanding			remaining		exercisable		remaining
Exercise		at end of			contractual		at end of		contractual
price		year			life (years)		year		life (years)
$	0.00-0.01		31,389	*)		-		31,389		-
$	2.21		2,313,143			5.94		2,312,101		5.94
$	11.06		52,000			9.39		-		-
$	11.52		346,500			9.47		43,312		9.47
$	16.00		213,109			6.03		161,062		5.37
$	17.63		968,328			8.68		319,132		8.52
$	23.19		210,000			7.78		105,000		7.78
$	23.42		16,000			7.77		8,000		7.77
$	23.84		595,268			7.95		313,184		7.94
$	23.86		69,400			7.75		39,035		7.75
$	24.97		21,900			7.42		13,687		7.42
$	28.96		18,875			6.84		18,875		6.84
$	30.66		26,400			7.53		14,848		7.53
$	30.93		20,000			6.81		20,000		6.81
$	36.74		3,000			6.93		2,250		6.93
$	40.21		45,072			7.19		32,777		7.19
$	49.68		233,000			7.05		160,187		7.05
$	59.2		13,000			6.94		9,750		6.94
$	64.61		25,010			7.12		17,194		7.12

*) Including 18,326 RSUs that were granted to the employees of Nanox AI at the completion of the merger and 13,063 RSUs that were issued in consideration for services.

Schedule of Share-Based Compensation Expenses

Share-based compensation expenses

	Year Ended December 31,
	2023		2022		2021
	(U.S. dollars in thousands)
Cost of revenue		56		99		51
Research and development		3,818		4,806		3,248
Sales and Marketing		484		997		2,442
General and administrative		2,480		12,721		13,065
		6,838		18,623		18,806